Stay updated with breaking news from Jaume Capdevila. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Approval based on data from the COSMIC-311 Phase III trial, in which Cabometyx® (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1This milestone marks the first treatment option to be specifically approved as a second-line therapy in this indicationDisclaimer: Intende...
Ipsen announces European Commission approval of the use of Cabometyx® (cabozantinib) as a monotherapy for the treatment of adult patients
Recommendation based on data from the COSMIC-311 Phase III trial, in which Cabometyx (cabozantinib) demonstrated a 78% reduction in risk of disease progression or death versus placebo1 Disclaimer:
email article The multitargeted tyrosine kinase inhibitor (TKI) lenvatinib induced a strong tumor response in patients with previously treated advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), according to results from a phase II trial in Europe. In this multicenter, open-label study involving 111 patients, treatment with lenvatinib (Lenvima) led to an overall response rate (ORR) of 29.9%, with a particularly high ORR -- 44.2% -- in patients with pancreatic NETs, reported Jaume Capdevila, MD, PhD, of Vall Hebron University Hospital in Barcelona, and colleagues . "Thi...